EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP)

Patrick Huber, Till Braunschweig, Hanna Frankenberger, Clemens Stihl, Moritz Gröger, Donata Gellrich, Manuel Lasch

European Archives of Oto-Rhino-Laryngology · 2026-06 · 283 (6) · 3809-3817

DOI: 10.1007/s00405-026-10187-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 29.04.2026. Verfasst von Patrick Huber und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, Munich, 81377, Germany. pat…. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Eosinophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation and frequently persists despite standard therapy. Dupilumab has proven efficacy, yet robust predictors of long-term response remain insufficiently defined. METHODS: In this monocentric, retrospective analysis, 163 adults with CRSwNP treated with dupilumab for ≥ 24 months were assessed at a tertiary referral center. Outcome parameters included nasal polyp score (NPS), sinonasal quality of life (SNOT-22), and olfactory function (SSIT). Treatment response was classified according to EUFOREA 2023 criteria. Archived polyp tissue from 72 patients obtained prior to Dupilumab treatment underwent histological reassessment, with eosinophilic infiltration quantified using absolute thresholds (Lee et al.: ≤10, 11–69, ≥ 70 eosinophils/HPF) and relative thresholds (Yang et al.: >20%). RESULTS: Dupilumab led to marked and sustained clinical improvements across the cohort (NPS − 4.6 ± 2.1; SNOT-22 − 44.1 ± 18.5; SSIT + 4.3 ± 2.9 at 24 months). Outcomes were independent of demographic factors, asthma, NERD, allergen sensitization, serum IgE, or blood eosinophils. In contrast, higher tissue eosinophilia correlated with enhanced short-term responses. Patients with > 20% eosinophils showed significantly greater SNOT-22 reduction at 12 months (p < 0.05). Stratification by ≥ 70 eosinophils/HPF and Yang’s classification (0–10, 11–69, ≥ 70) consistently showed superior trajectories in high-grade eosinophilia. EUFOREA response rates were highest in these subgroups, with no non-responders observed. CONCLUSION: Dupilumab achieved durable benefit across all patient subgroups, while elevated tissue eosinophilia predicted faster and more pronounced short-term improvements. Systematic eosinophil quantification may refine patient stratification and optimize biologic therapy allocation in CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsAntibodies, Monoclonal, HumanizedEosinophiliaRhinitisSinusitisHumansFemaleChronic DiseaseMaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeQuality of LifeEosinophilsAged

Stichwörter der Autor:innen

BiomarkerbiomarkerCRSwNPDupilumabTissue eosinophiliaType-2 inflammation

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, Munich, 81377, Germany. patrick.huber@med.uni-muenchen.de.
  • Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany.
  • Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, Munich, 81377, Germany.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Huber, P., Braunschweig, T., Frankenberger, H., Stihl, C., Gröger, M., Gellrich, D., & Lasch, M. (2026). Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP). European Archives of Oto-Rhino-Laryngology, 283(6), 3809-3817. https://doi.org/10.1007/s00405-026-10187-y

Vancouver

Huber P, Braunschweig T, Frankenberger H, Stihl C, Gröger M, Gellrich D, et al. Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP). European Archives of Oto-Rhino-Laryngology. 2026;283(6):3809-3817. doi:10.1007/s00405-026-10187-y

BibTeX
@article{Huber2026,
  author = {Huber, Patrick and Braunschweig, Till and Frankenberger, Hanna and Stihl, Clemens and Gröger, Moritz and Gellrich, Donata and Lasch, Manuel},
  title = {Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP)},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  volume = {283},
  number = {6},
  pages = {3809--3817},
  doi = {10.1007/s00405-026-10187-y}
}
Kostenlos starten →